These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37701441)

  • 1. Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1.
    Mabbitt J; Holyer ID; Roper JA; Nilsson UJ; Zetterberg FR; Vuong L; Mackinnon AC; Pedersen A; Slack RJ
    Front Immunol; 2023; 14():1250559. PubMed ID: 37701441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gal-3 blocks the binding between PD-1 and pembrolizumab.
    Greisen SR; Bendix M; Nielsen MA; Pedersen K; Jensen NH; Hvid M; Mikkelsen JH; Drace T; Boesen T; Steiniche T; Schmidt H; Deleuran B
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39357979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
    Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
    Vuong L; Kouverianou E; Rooney CM; McHugh BJ; Howie SEM; Gregory CD; Forbes SJ; Henderson NC; Zetterberg FR; Nilsson UJ; Leffler H; Ford P; Pedersen A; Gravelle L; Tantawi S; Schambye H; Sethi T; MacKinnon AC
    Cancer Res; 2019 Apr; 79(7):1480-1492. PubMed ID: 30674531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy
    Wang Y; Rousset X; Prunier C; Garcia P; Dosda E; Leplus E; Viallet J
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
    Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
    Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-3 interacts with PD-1 and counteracts the PD-1 pathway-driven regulation of T cell and osteoclast activity in Rheumatoid Arthritis.
    Pedersen K; Nielsen MA; Juul-Madsen K; Hvid M; Deleuran B; Greisen SR
    Scand J Immunol; 2023 Feb; 97(2):e13245. PubMed ID: 36537046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?
    Bailly C; Thuru X; Quesnel B
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
    Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
    Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biophysical and Immunological Characterization and
    Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
    Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
    Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
    Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
    Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
    Li E; Xu J; Chen Q; Zhang X; Xu X; Liang T
    Immunotherapy; 2023 Feb; 15(3):135-147. PubMed ID: 36779368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 20. BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells.
    Górniak P; Wasylecka-Juszczyńska M; Ługowska I; Rutkowski P; Polak A; Szydłowski M; Juszczyński P
    Mol Oncol; 2020 Aug; 14(8):1817-1832. PubMed ID: 32330348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.